Genetic Full Cancer Risk
A comprehensive genetic screening panel assessing variants in 113 genes associated with inherited cancer risk, including both common and rarer cancer-predisposition syndromes.
What does it check?
- Breast, ovarian, and gynecological cancer genes (BRCA1, BRCA2, PALB2, etc.)
- Gastrointestinal and colorectal cancer genes (Lynch syndrome, APC, MUTYH, etc.)
- Prostate and renal cell cancer predisposition markers
- Melanoma, endocrine, and thyroid neoplasia genes (CDKN2A, RET, MEN1)
- Rare multi-system cancer predisposition syndromes (Li-Fraumeni, Cowden, von Hippel-Lindau)
Who may benefit?
Individuals seeking comprehensive insight into hereditary cancer risk, especially those with multi-generational or diverse cancer diagnoses in their family.
Genetic Full Cancer Risk
What is it?
A comprehensive genetic screening panel assessing variants in 113 genes associated with inherited cancer risk, including both common and rarer cancer-predisposition syndromes.
Who may benefit?
Individuals seeking comprehensive insight into hereditary cancer risk, especially those with multi-generational or diverse cancer diagnoses in their family.
Important information
Comprehensive genetic counselling is included before and after testing. Not all cancers are hereditary (most are sporadic), and a negative panel does not eliminate standard population cancer risks.